Potency of antihypertensive therapy with Azilsartan on Walking Activity among Peripheral Artery Disease Patients With hypertention and Intermittent Claudicatio
Not Applicable
- Conditions
- Peripheral artery disease
- Registration Number
- JPRN-UMIN000013670
- Lead Sponsor
- Sakakibara heart Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
Not provided
Exclusion Criteria
1 Patient with Critical limb ischemia 2 Life expectancy 6months 3 Medication with Cablocker or At1receptor blocker 4 inappropriate patient determined from study director
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method recovery ability index(RAI) in walking exercise near infrared spectroscopy
- Secondary Outcome Measures
Name Time Method 1 absolute claudication distance, exercise time and Deoxygenated hemoglobin recovery time in walking exercise near infrared spectroscopy. WIQ score. 2 Anckle Brachial pressure Index,Pulse Wave Verocity,flow mediated vasodilatation,LF/HF in holter ECG, meanHR in holter ECG. 3 Blood pressure in Examination room. Mean blood pressure and Blood Pressure Type in 24hr. Ambulatory Blood Pressure Measurement. 4 Myocardial infarction, stroke and acute heart failure required hospitalization. 5 Adverse event of drug
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Azilsartan's effect on walking activity in peripheral artery disease patients with hypertension and intermittent claudication?
How does Azilsartan compare to standard-of-care antihypertensives in improving walking distance and reducing claudication symptoms in peripheral artery disease patients?
Are there specific biomarkers that predict response to Azilsartan in peripheral artery disease patients with intermittent claudication and hypertension?
What adverse events are associated with Azilsartan therapy in peripheral artery disease patients, and how can they be managed effectively?
What combination therapies or alternative drugs show promise for treating peripheral artery disease and hypertension alongside Azilsartan?